4SCAR T cells
PreclinicalCell therapy
4SCAR T cells is one of 32 therapeutic programs targeting Autoimmune Diseases. It is currently in Preclinical.
3
Indications
2
Total Trials
2
Active Trials
31
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
4SCAR T cells
SShenzhen Geno-Immune Medical Institute
Preclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
Tc99m Sestamibi
MM.D. Anderson Cancer Center
Preclinical
Ibrance
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for 4SCAR T cells. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy
- Highest Phase
- Preclinical[1]